Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)

Warfarin is an oral anticoagulant that is widely prescribed to prevent thromboembolic events in persons at increased risk. The optimal dose is difficult to establish because it can vary 10-fold among individuals due to clinical and demographic factors. Testing for variants of the vitamin K epoxide r...

Descripción completa

Detalles Bibliográficos
Autor principal: Grossniklaus, Daurice
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Evidence on Genomic Tests
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940214/
https://www.ncbi.nlm.nih.gov/pubmed/20877452
http://dx.doi.org/10.1371/currents.RRN1155
_version_ 1782186814027595776
author Grossniklaus, Daurice
author_facet Grossniklaus, Daurice
author_sort Grossniklaus, Daurice
collection PubMed
description Warfarin is an oral anticoagulant that is widely prescribed to prevent thromboembolic events in persons at increased risk. The optimal dose is difficult to establish because it can vary 10-fold among individuals due to clinical and demographic factors. Testing for variants of the vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) genes has been proposed for use in guiding the initial dose of warfarin, thus achieving optimal dosing more quickly and with lower risk of bleeding.
format Text
id pubmed-2940214
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29402142010-09-28 Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment) Grossniklaus, Daurice PLoS Curr Evidence on Genomic Tests Warfarin is an oral anticoagulant that is widely prescribed to prevent thromboembolic events in persons at increased risk. The optimal dose is difficult to establish because it can vary 10-fold among individuals due to clinical and demographic factors. Testing for variants of the vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) genes has been proposed for use in guiding the initial dose of warfarin, thus achieving optimal dosing more quickly and with lower risk of bleeding. Public Library of Science 2010-09-14 /pmc/articles/PMC2940214/ /pubmed/20877452 http://dx.doi.org/10.1371/currents.RRN1155 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Evidence on Genomic Tests
Grossniklaus, Daurice
Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
title Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
title_full Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
title_fullStr Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
title_full_unstemmed Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
title_short Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
title_sort testing of vkorc1 and cyp2c9 alleles to guide warfarin dosing: test category: pharmacogenomic (treatment)
topic Evidence on Genomic Tests
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940214/
https://www.ncbi.nlm.nih.gov/pubmed/20877452
http://dx.doi.org/10.1371/currents.RRN1155
work_keys_str_mv AT grossniklausdaurice testingofvkorc1andcyp2c9allelestoguidewarfarindosingtestcategorypharmacogenomictreatment

Ejemplares similares